15.38 USD
+4.25 (+38.19%)
15.37 USD
-0.01 (-0.07%)
Taking everything into account, DVAX scores 6 out of 10 in our fundamental rating. DVAX was compared to 530 industry peers in the Biotechnology industry. Both the profitability and the financial health of DVAX get a neutral evaluation. Nothing too spectacular is happening here. DVAX is not overvalued while it is showing excellent growth. This is an interesting combination. This makes DVAX very considerable for growth investing!
1. Profitability
1.1 Basic Checks
DVAX had positive earnings in the past year.
In the past year DVAX had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: DVAX reported negative net income in multiple years.
Of the past 5 years DVAX 4 years had a positive operating cash flow.
1.2 Ratios
DVAX has a better Return On Assets (-4.59%) than 86.04% of its industry peers.
The Return On Equity of DVAX (-8.13%) is better than 88.30% of its industry peers.
DVAX has a better Return On Invested Capital (1.05%) than 89.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.59% | ||
| ROE | -8.13% | ||
| ROIC | 1.05% |
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DVAX's Profit Margin has declined in the last couple of years.
DVAX has a better Operating Margin (3.16%) than 89.43% of its industry peers.
With an excellent Gross Margin value of 83.17%, DVAX belongs to the best of the industry, outperforming 86.23% of the companies in the same industry.
In the last couple of years the Gross Margin of DVAX has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.16% | ||
| PM (TTM) | N/A | ||
| GM | 83.17% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), DVAX is destroying value.
Compared to 1 year ago, DVAX has less shares outstanding
DVAX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for DVAX is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.50 indicates that DVAX is not a great score, but indicates only limited risk for bankruptcy at the moment.
DVAX has a better Altman-Z score (2.50) than 66.79% of its industry peers.
The Debt to FCF ratio of DVAX is 3.24, which is a good value as it means it would take DVAX, 3.24 years of fcf income to pay off all of its debts.
DVAX has a Debt to FCF ratio of 3.24. This is amongst the best in the industry. DVAX outperforms 92.83% of its industry peers.
DVAX has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.49, DVAX is doing worse than 72.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 3.24 | ||
| Altman-Z | 2.5 |
ROIC/WACC0.13
WACC8.32%
2.3 Liquidity
DVAX has a Current Ratio of 7.62. This indicates that DVAX is financially healthy and has no problem in meeting its short term obligations.
DVAX has a Current ratio of 7.62. This is in the better half of the industry: DVAX outperforms 72.83% of its industry peers.
A Quick Ratio of 6.94 indicates that DVAX has no problem at all paying its short term obligations.
DVAX has a Quick ratio of 6.94. This is in the better half of the industry: DVAX outperforms 70.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.62 | ||
| Quick Ratio | 6.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 211.54% over the past year.
DVAX shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -19.10% yearly.
The Revenue has grown by 26.73% in the past year. This is a very strong growth!
Measured over the past years, DVAX shows a very strong growth in Revenue. The Revenue has been growing by 51.10% on average per year.
EPS 1Y (TTM)211.54%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)26.73%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%17.67%
3.2 Future
DVAX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 63.12% yearly.
The Revenue is expected to grow by 15.42% on average over the next years. This is quite good.
EPS Next Y-318.17%
EPS Next 2Y72.81%
EPS Next 3Y63.12%
EPS Next 5YN/A
Revenue Next Year21.89%
Revenue Next 2Y18.83%
Revenue Next 3Y17.54%
Revenue Next 5Y15.42%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 37.51, DVAX can be considered very expensive at the moment.
Based on the Price/Earnings ratio, DVAX is valued cheaply inside the industry as 91.70% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.59. DVAX is valued slightly more expensive when compared to this.
DVAX is valuated quite expensively with a Price/Forward Earnings ratio of 28.61.
92.45% of the companies in the same industry are more expensive than DVAX, based on the Price/Forward Earnings ratio.
DVAX is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 24.03, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.51 | ||
| Fwd PE | 28.61 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DVAX is valued cheaply inside the industry as 90.19% of the companies are valued more expensively.
94.53% of the companies in the same industry are more expensive than DVAX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.42 | ||
| EV/EBITDA | 69.7 |
4.3 Compensation for Growth
DVAX has a very decent profitability rating, which may justify a higher PE ratio.
DVAX's earnings are expected to grow with 63.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y72.81%
EPS Next 3Y63.12%
5. Dividend
5.1 Amount
No dividends for DVAX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
15.38
+4.25 (+38.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.65%
Inst Owner Change-1.38%
Ins Owners0.5%
Ins Owner Change-12.15%
Market Cap1.81B
Revenue(TTM)330.51M
Net Income(TTM)-43.40M
Analysts80
Price Target21.17 (37.65%)
Short Float %12.25%
Short Ratio9.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.4%
Min EPS beat(2)30.1%
Max EPS beat(2)64.71%
EPS beat(4)3
Avg EPS beat(4)6.21%
Min EPS beat(4)-86.66%
Max EPS beat(4)64.71%
EPS beat(8)6
Avg EPS beat(8)-6.9%
EPS beat(12)9
Avg EPS beat(12)66.09%
EPS beat(16)11
Avg EPS beat(16)67.73%
Revenue beat(2)1
Avg Revenue beat(2)3.46%
Min Revenue beat(2)-1.05%
Max Revenue beat(2)7.97%
Revenue beat(4)1
Avg Revenue beat(4)-0.31%
Min Revenue beat(4)-4.19%
Max Revenue beat(4)7.97%
Revenue beat(8)2
Avg Revenue beat(8)-2.29%
Revenue beat(12)6
Avg Revenue beat(12)3.06%
Revenue beat(16)8
Avg Revenue beat(16)4.4%
PT rev (1m)-13.54%
PT rev (3m)-13.54%
EPS NQ rev (1m)144.47%
EPS NQ rev (3m)-45%
EPS NY rev (1m)12%
EPS NY rev (3m)7.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.77%
Revenue NY rev (1m)1.13%
Revenue NY rev (3m)1.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.51 | ||
| Fwd PE | 28.61 | ||
| P/S | 5.46 | ||
| P/FCF | 22.42 | ||
| P/OCF | 19.93 | ||
| P/B | 3.38 | ||
| P/tB | 3.39 | ||
| EV/EBITDA | 69.7 |
EPS(TTM)0.41
EY2.67%
EPS(NY)0.54
Fwd EY3.5%
FCF(TTM)0.69
FCFY4.46%
OCF(TTM)0.77
OCFY5.02%
SpS2.81
BVpS4.55
TBVpS4.53
PEG (NY)N/A
PEG (5Y)N/A
Graham Number6.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.59% | ||
| ROE | -8.13% | ||
| ROCE | 1.24% | ||
| ROIC | 1.05% | ||
| ROICexc | 3.98% | ||
| ROICexgc | 4.02% | ||
| OM | 3.16% | ||
| PM (TTM) | N/A | ||
| GM | 83.17% | ||
| FCFM | 24.37% |
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 3.24 | ||
| Debt/EBITDA | 20.41 | ||
| Cap/Depr | 429.21% | ||
| Cap/Sales | 3.05% | ||
| Interest Coverage | 2.16 | ||
| Cash Conversion | 708.62% | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.62 | ||
| Quick Ratio | 6.94 | ||
| Altman-Z | 2.5 |
F-Score5
WACC8.32%
ROIC/WACC0.13
Cap/Depr(3y)139.55%
Cap/Depr(5y)160.56%
Cap/Sales(3y)1.68%
Cap/Sales(5y)6.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)211.54%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y-318.17%
EPS Next 2Y72.81%
EPS Next 3Y63.12%
EPS Next 5YN/A
Revenue 1Y (TTM)26.73%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%17.67%
Revenue Next Year21.89%
Revenue Next 2Y18.83%
Revenue Next 3Y17.54%
Revenue Next 5Y15.42%
EBIT growth 1Y240.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year458.87%
EBIT Next 3Y103.78%
EBIT Next 5YN/A
FCF growth 1Y-31.63%
FCF growth 3Y-43.07%
FCF growth 5YN/A
OCF growth 1Y-25.53%
OCF growth 3Y-41.69%
OCF growth 5YN/A
DYNAVAX TECHNOLOGIES CORP / DVAX FAQ
What is the fundamental rating for DVAX stock?
ChartMill assigns a fundamental rating of 6 / 10 to DVAX.
What is the valuation status for DVAX stock?
ChartMill assigns a valuation rating of 6 / 10 to DYNAVAX TECHNOLOGIES CORP (DVAX). This can be considered as Fairly Valued.
Can you provide the profitability details for DYNAVAX TECHNOLOGIES CORP?
DYNAVAX TECHNOLOGIES CORP (DVAX) has a profitability rating of 6 / 10.
What is the expected EPS growth for DYNAVAX TECHNOLOGIES CORP (DVAX) stock?
The Earnings per Share (EPS) of DYNAVAX TECHNOLOGIES CORP (DVAX) is expected to decline by -318.17% in the next year.